All In Biotech

Drug Trial Radar · NCT04137562

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

118

Actual

Start

Dec 11, 2019

Primary completion

Jan 26, 2023

Study completion Oct 31, 2027

Sponsor

Lead sponsor
EHL Bio Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis. The aim of this study is to evaluate the safety and efficacy of ADSTEM Inj. against Placebo in the treatment of atopic dermatitis in patients with moderate to severe acute and chronic atopic.

Conditions

  • Atopic Dermatitis

Interventions

  • ADSTEM Inj.Biological

    Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL

  • PlaceboOther

    330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EASI-50Time frame: 16 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Chungnam National University Hospital

    Daejeon, Chungcheongnam-do, South Korea

  • Korea University AnSan Hospital

    Ansan, Gyeonggi-do, South Korea

  • Chung-Ang University Hospital

    Seoul, Seoulteukbyeolsi, South Korea

  • Kyunghee University Medical Center

    Seoul, Seoulteukbyeolsi, South Korea

  • Seoul National University Hospital

    Seoul, Seoulteukbyeolsi, South Korea

  • SMG-SNU Boramae Medical Center

    Seoul, Seoulteukbyeolsi, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.